Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors

Layer, Richard T., Skolnick, Phil, Bertha, Craig M., Bandarage, Upul K., Kuehne, Martin E., Popik, Piotr · 1996 · European Journal of Pharmacology

AI-extracted · unverified · confirm at source

Ibogaine most potent NMDA antagonist in series (Kᵢ = 1.1 μM); O-desmethylibogaine ~5× weaker. Only ibogaine attenuated naloxone-precipitated withdrawal in mice, supporting NMDA-mediated anti-addictive mechanism.

Dosing: 40–80 mg/kg ibogaine (mouse, i.p.) (intraperitoneal)